No Benefit of High Dose Methotrexate (HD-MTX) in Intermediate Risk Childhood Acute Lymphoblastic Leukemia (ALL): Results of 2 Randomised Multicenter Trials in Russia

被引：0
|
作者：
Karachunskiy, A. [1 ]
Ponomareva, N. [2 ]
Roumiantseva, J. [1 ]
Aleynikova, O. [3 ]
Arakaev, O. [4 ]
Litvinov, D. [1 ]
Karelin, A. [1 ]
Boychenko, E. [5 ]
Sharapova, G. [6 ]
Lagoyko, S. [1 ]
Bydanov, O. [3 ]
Henze, G. [7 ]
机构：
[1] Fed Res Ctr Paediat Haematol Oncol & Immunol, Inst Oncol Radiol & Nucl Med, Moscow, Russia
[2] Russian Childrens Clin Hosp, Dept Haematol, Moscow, Russia
[3] Republ Clin Res Ctr Paediat Haematol Oncol & Immu, Dept Haematol Oncol, Minsk, BELARUS
[4] Reg Childrens Hosp, Paediat Oncohematol Ctr, Ekaterinburg, Russia
[5] St Petersburg Municipal Children Hosp 1, Dept Haematol, St Petersburg, Russia
[6] Reg Childrens Clin Hosp, Dept Haematol, Nizhnevartovsk, Russia
[7] Charite Univ Med Berlin, Dept Paediat Oncol Haematol, Berlin, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-089
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Vincristine (VCR)-Dexamethasone (DEXA) pulses for intermediate risk (IR) childhood acute lymphoblastic leukemia (ALL) treated with BFM based protocols: Results of the I-BFM-SG ALL IR 95 study.
    Conter, V
    Valsecchi, MG
    Silvestri, D
    Campbell, M
    Dibar, EA
    Magyarosy, E
    Gadner, H
    Stary, J
    Benoit, Y
    Riehm, H
    Masera, G
    Schrappe, M
    BLOOD, 2005, 106 (11) : 8A - 8A
  • [42] Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study
    Clement, Laura
    Suciu, Stefan
    Luquet, Isabelle
    Ferster, Alina
    Yakouben, Karima
    Uytterbroeck, Anne
    Paillard, Catherine
    Sirvent, Nicolas
    Costa, Vitor
    De Moerloose, Barbara
    Mazingue, Francoise
    Plouvier, Emmanuel
    Munzer, Martine
    Poiree, Maryline
    Minckes, Odile
    Millot, Frederic
    Plantaz, Dominique
    Piette, Caroline
    Speleman, Frank
    Cave, Helene
    VanderWerff-TenBossch, Jutte
    Rohrlich, Pierre Simon
    Bertrand, Yves
    Benoit, Yves
    Plat, Genevieve
    BLOOD, 2016, 128 (22)
  • [43] High dose methotrexate (HD MTX at 2 gr/sqm x 4) associated to extended intrathecal (IT) chemotherapy is effective for prevention of central nervous system (CNS) relapse in childhood ALL treated with BFM systemic therapy.
    Conter, V
    Rizari, C
    Valsecchi, MG
    Silvestri, D
    Aricò, M
    Barisone, E
    Casale, F
    De Rossi, G
    Locatelli, F
    Lo Nigro, L
    Messina, C
    Micalizzi, C
    Pession, A
    Parasole, R
    Rondelli, R
    Santoro, N
    Testi, AM
    Jankovic, M
    Basso, G
    Biondi, A
    Masera, G
    BLOOD, 2005, 106 (11) : 8A - 8A
  • [44] Impact of SLCO1B1 521T > C Variant on Leucovorin Rescue and Risk of Relapse in Childhood Acute Lymphoblastic Leukemia Treated With High-Dose Methotrexate
    Zhang, Hua-Nian
    He, Xue-Lian
    Wang, Cheng
    Wang, Yang
    Chen, Yu-Jun
    Li, Jian-Xin
    Niu, Chang-He
    Gao, Ping
    PEDIATRIC BLOOD & CANCER, 2014, 61 (12) : 2203 - 2207
  • [45] Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate-to high-dose methotrexate
    Zajac-Spychala, Olga
    Pawlak, Mikolaj
    Karmelita-Katulska, Katarzyna
    Pilarczyk, Jakub
    Jonczyk-Potoczna, Katarzyna
    Przepiora, Agnieszka
    Derwich, Katarzyna
    Wachowiak, Jacek
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2342 - 2351
  • [46] High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40: Results From the Dutch-Belgian HOVON-70 Study
    Rijneveld, A. W.
    van der Holt, B.
    Daenen, S. M. G. J.
    Biemond, B. J.
    van de Loosdrecht, A. A.
    de Weerdt, O.
    Muus, P.
    Maertens, J.
    Mattijssen, V.
    Demuynck, H.
    Legdeur, Mcjc
    Wijermans, P. W.
    Wittebol, S.
    Spoelstra, F.
    Dekker, A. W.
    Ossenkoppele, G. J.
    Cornelissen, J. J.
    Willemze, R.
    BLOOD, 2009, 114 (22) : 136 - 137
  • [47] High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients
    Cario, Gunnar
    Mitlohner, Rita
    Zimmermann, Martin
    Romey, Renja
    Rhein, Peter
    Schrauder, Andre
    Moericke, Anja
    Bourquin, Jean-Pierre
    Ludwig, Wolf-Dieter
    Ratei, Richard
    Schrappe, Martin
    Karawajew, Leonid
    Stanulla, Martin
    BLOOD, 2011, 118 (21) : 337 - 338
  • [48] Therapeutic impact of extended high-dose asparaginase during continuation therapy for standard-risk childhood acute lymphoblastic leukemia. Long term results of the IDH-ALL-91 trial of the International BFM Study Group.
    Arico, M
    Valsecchi, MG
    Pession, A
    Kamps, WA
    Magyarosy, E
    Rizzari, C
    Van Wering, ER
    Lo Nigro, L
    van der Does, A
    Locatelli, F
    Basso, G
    Masera, G
    BLOOD, 2003, 102 (11) : 878A - 878A
  • [49] Association of ABCC2 -24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia (vol 9, e82681, 2014)
    不详
    PLOS ONE, 2014, 9 (03):
  • [50] Matched Unrelated Donor Allogeneic Stem Cell Transplantation in High Risk Acute Lymphoblastic Leukemia (ALL) After a Preparative Regimen of Hyperfractionated Total Body Irradiation and High-Dose Etoposide - A Feasibility Study within the German Multicenter Study Group for Adult ALL
    Beelen, Dietrich W.
    Arnold, Renate
    Terwey, Theis
    Steckel, Nina K.
    Goekbuget, Nicola
    Dieter, Hoelzer
    BLOOD, 2009, 114 (22) : 1316 - 1316
12345